Using AI, Insilico Medicine Finds A Potential New Target For Gynaecological And Breast Malignancies
As a promising new therapeutic target for breast and gynaecological cancer, MYT1 has been identified by Insilico Medicine (“Insilico”), a clinical stage generative artificial intelligence (AI)-driven drug discovery company. Insilico Medicine has also discovered a series of novel, potent, and highly selective inhibitors that specifically target MYT1. These results, which were published in the Journal of Medicinal Chemistry in December 2023, were backed by Insilico’s AI-driven generative biology and chemistry engine . Insilico Medicine Finds Breast and gynaecological malignancies are major global health and reproductive hazards to women’s quality of life. The research team uses Insilico Medicine’s unique AI-driven target identification platform, PandaOmics, to analyse data of five types of gynaecological cancers, including ovarian, endometrial, cervical, and breast cancer, especially triple-negative breast cancer, in order to find possible targets for new therapeutics. Inter...